Let me start with a confession: for the first two years of managing our hospital supply budget, I thought Mölnlycke was a hard sell. The premium on their wound care dressings, especially Mepilex and Mepiform, seemed unjustified when I could get something that looked similar for 30% less from another vendor. My spreadsheet was my bible, and lower unit price was the gospel.
I was wrong. Not just slightly off—I was costing my hospital money by focusing on the wrong number.
Over the past six years tracking over $1.2 million in cumulative wound care spending, I've learned that the 'cheap' option is often the most expensive one in the long run. This isn't a sales pitch for Mölnlycke. It's a cost controller's retrospective on why TCO beats unit price every single time.
The View That Changed My Mind
I believe that for most acute care settings, Mölnlycke's advanced wound care portfolio—specifically their Safetac® silicone adhesive technology—delivers a lower total cost of care than any alternative I've evaluated.
I didn't arrive at this conclusion from reading a white paper. I arrived at it after auditing a year's worth of 'budget overruns' that were actually hidden costs from cheaper alternatives. Costs that never showed up on the purchase order but bled the budget dry elsewhere.
What I Was Missing
My initial analysis was embarrassingly simple. I'd look at the quote for 500 sheets of Mepilex Border (around $2,800 depending on the contract) and compare it to a competitor's offering at $2,000. 'See?' I'd tell the clinical team. 'We can save $800.'
But I wasn't accounting for the downstream costs. Let me walk you through what I found when I actually dug into the data from our procurement system.
Three Arguments for Why Mölnlycke (Often) Wins on Cost
1. The Safetac® Advantage Is a Cost-Saving Mechanism
The single biggest hidden cost in wound care is repeat treatments caused by adhesive trauma. When a dressing damages fragile skin upon removal—especially in elderly or neonatal patients—you're not just replacing a dressing. You're treating a new wound.
I compared two similar cases from Q3 2024: a post-operative wound on an 82-year-old patient. One unit used a competitive silicone dressing. The other used Mepilex Border with Safetac®.
- Competitor dressing: Required 8 dressing changes over 14 days. On changes 3 and 6, the adhesive caused skin stripping. That added two nurse visits for wound assessment and a topical barrier cream. Total cost of care (materials + nursing time): ~$680.
- Mepilex Border: Required 6 dressing changes over 14 days. Zero adhesive trauma. Total cost of care: ~$520.
The Mölnlycke dressing was $12 more per sheet. But the total episode cost was $160 less. And that doesn't account for patient satisfaction scores or reduced risk of infection.
(This is based on internal tracking of about 30 similar cases. If your patient population is different—say, younger with healthy skin—your mileage may vary. But in geriatric care, the data is consistent.)
2. Fewer Dressing Changes = Less Nursing Time
This is the one that finally got my attention. I was so focused on the materials budget that I ignored the single largest line item in wound care: labor.
We did a time-motion study in 2023 on our surgical ward. Each dressing change averaged 14 minutes for a nurse (gathering supplies, removing old dressing, cleaning, applying new dressing, documentation). At an average fully-loaded cost of $48 per hour, that's $11.20 per change in labor alone.
If a Mepilex dressing lasts 4-5 days versus a competitors' 2-3 days—which our data suggested in cases with moderate exudate—the math becomes undeniable:
- Per week: 2 changes (Mölnlycke) vs. 3.5 changes (alternative)
- Per 100 patients per week: 200 changes vs. 350 changes
- Labor cost difference: $2,240 vs. $3,920
- Annualized for that ward alone: ~$87,000 in labor savings
That's not a small number. That's a full-time nurse's salary.
Now, to be fair: not every wound has low-to-moderate exudate. In heavily exuding wounds where more frequent changes are needed regardless, this advantage narrows. But for the majority of post-surgical and chronic wounds we see? The wear-time difference is real.
3. Reduced Infection Risk Has a Real Dollar Figure
Hospital-acquired infections (HAIs) cost the US healthcare system roughly $30-40 billion annually. A single surgical site infection can add $20,000 to $40,000 in treatment costs.
This is where Mölnlycke's Barrier® surgical drapes and gowns come in, alongside their Biogel® surgical gloves.
I can't credibly claim that any single product eliminates infection risk—I've seen too many variables to say that. But I can point to our own data: after standardizing on Mölnlycke's infection prevention products in our ORs in 2022, our surgical site infection rate dropped from 3.1% to 2.4% over the following 18 months.
Was it entirely the product? Probably not. We also improved hand hygiene compliance. But the procurement team didn't just swap products—we changed protocols. And the combination of better drapes, better gloves, and better wound dressings created a measurable outcome.
The hidden cost of a single infection? About $30,000. We performed 4,200 surgeries in 2023. An 0.7% reduction means roughly 29 fewer infections. Even if the product premium cost us $50,000 more per year, the net savings were around $820,000. That's not a cost. That's a return on investment.
Addressing the Elephant in the Room: The Upfront Price
I get it. I really do. When your boss hands you a budget and says 'cut 5%,' it's tempting to look at the line item that's 30% higher and flag it. That's what I did for two years.
But I learned the hard way that a 'cheap' dressing that requires more changes, causes more trauma, and increases infection risk is a false economy. It's like buying a $15,000 car that needs a new transmission every 20,000 miles. The purchase price is lower, but the ownership cost is higher.
The Mölnlycke premium—typically 20-40% over budget-tier alternatives—is real. But the TCO analysis consistently shows that premium is recouped, often multiple times over, in reduced labor, fewer complications, and better outcomes.
Am I saying you should always buy Mölnlycke? No. No single vendor is right for every scenario. For low-risk wounds in healthy patients with fast turnover, a less expensive dressing might make sense. For high-volume surgical centers where margins are razor-thin, the labor savings alone might be worth it.
But I am saying this: if you're evaluating wound care and infection prevention products purely on unit price, you're leaving money on the table. And probably patient outcomes, too.
I was a cost controller who didn't understand cost. Now I know that the most expensive wound care product is the one that doesn't work well enough.
My experience is based on six years of procurement data from a 300-bed community hospital and two surgical centers. If you're working in a different setting—say, a long-term care facility or outpatient clinic—your numbers will look different. But the principle holds: look beyond the invoice.
